首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17A |
| Uniprot No | Q16552 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24 -155aa |
| 氨基酸序列 | GITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSP WNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLR REPPHCPNSFRLEKILVSVGCTCVTPIVHHVA |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-17A重组蛋白的典型参考文献及其摘要概括：
1. **"IL-17A structure and signaling in autoimmune inflammation"**
*作者：Gaffen SL, Jain R*
摘要：解析IL-17A的晶体结构，揭示其与受体IL-17RA/IL-17RC复合物的结合模式，并阐述其在银屑病、类风湿性关节炎等自身免疫疾病中激活NF-κB和MAPK信号通路的机制。
2. **"Recombinant human IL-17A induces inflammatory responses in a psoriasis-like mouse model"**
*作者：Johansen C et al.*
摘要：通过重组IL-17A蛋白注射小鼠，证明其可诱导皮肤炎症、角质细胞过度增殖和促炎因子(如IL-6、TNF-α)释放，为IL-17A靶向疗法在银屑病中的应用提供实验依据。
3. **"High-yield production of bioactive recombinant IL-17A in E. coli and functional characterization"**
*作者：Zhang Y et al.*
摘要：报道利用大肠杆菌表达系统高效制备具有生物活性的重组IL-17A蛋白，并通过体外实验验证其促进成纤维细胞分泌IL-8和CXCL1的能力，优化纯化工艺以提升蛋白稳定性。
*注：以上文献信息为简化示例，实际引用需核对具体论文标题、作者及期刊来源。建议通过PubMed或Web of Science以“IL-17A recombinant protein”为关键词筛选近五年高被引论文。*
**Background of IL-17A Recombinant Protein**
Interleukin-17A (IL-17A), a key pro-inflammatory cytokine, belongs to the IL-17 family and is primarily secreted by T helper 17 (Th17) cells, mast cells, and innate lymphoid cells. Discovered in the 1990s, IL-17A plays a central role in host defense against extracellular pathogens and in the pathogenesis of autoimmune and chronic inflammatory diseases, such as psoriasis, rheumatoid arthritis, and multiple sclerosis. It exerts biological effects by binding to the IL-17 receptor (IL-17R) complex, activating downstream signaling pathways (e.g., NF-κB, MAPK), and inducing the production of antimicrobial peptides, chemokines, and other pro-inflammatory mediators.
Recombinant IL-17A protein is engineered *in vitro* using genetic modification techniques, typically expressed in mammalian systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and bioactivity. This purified protein retains the functional properties of native IL-17A, enabling researchers to study its role in immune regulation, inflammation, and tissue remodeling.
In research, recombinant IL-17A is widely used to model inflammatory conditions, screen therapeutic agents (e.g., anti-IL-17 monoclonal antibodies like secukinumab), and explore mechanisms of immune dysregulation. Its therapeutic targeting has revolutionized treatment for diseases like psoriasis, highlighting its clinical relevance. However, excessive IL-17A signaling is linked to pathological inflammation, underscoring the need for precise regulation.
Recent studies also investigate IL-17A's dual role in cancer and tissue repair, revealing context-dependent effects. As a research tool, recombinant IL-17A remains indispensable for advancing immunology and drug development.
×
